NASDAQ:AMRS

Amyris Stock Forecast, Price & News

$15.24
-0.42 (-2.68 %)
(As of 06/15/2021 04:51 PM ET)
Add
Compare
Today's Range
$14.89
$15.88
50-Day Range
$10.82
$18.23
52-Week Range
$1.88
$23.42
Volume2.55 million shs
Average Volume4.49 million shs
Market Capitalization$4.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.1
30 days | 90 days | 365 days | Advanced Chart
Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter.


Amyris logo

About Amyris

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.34 out of 5 stars

Basic Materials Sector

242nd out of 894 stocks

Industrial Organic Chemicals Industry

15th out of 40 stocks

Analyst Opinion: 2.5Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Amyris (NASDAQ:AMRS) Frequently Asked Questions

Is Amyris a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amyris stock.
View analyst ratings for Amyris
or view top-rated stocks.

What stocks does MarketBeat like better than Amyris?

Wall Street analysts have given Amyris a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amyris wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Amyris' next earnings date?

Amyris is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Amyris
.

How were Amyris' earnings last quarter?

Amyris, Inc. (NASDAQ:AMRS) posted its earnings results on Thursday, May, 6th. The biotechnology company reported ($1.08) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.92. The biotechnology company had revenue of $176.90 million for the quarter, compared to analysts' expectations of $73.36 million. Amyris's revenue was up 507.9% on a year-over-year basis.
View Amyris' earnings history
.

How has Amyris' stock been impacted by COVID-19 (Coronavirus)?

Amyris' stock was trading at $2.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMRS shares have increased by 414.9% and is now trading at $15.24.
View which stocks have been most impacted by COVID-19
.

When did Amyris' stock split? How did Amyris' stock split work?

Amyris shares reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

What guidance has Amyris issued on next quarter's earnings?

Amyris issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $400 million-$400 million, compared to the consensus revenue estimate of $337.46 million.

What price target have analysts set for AMRS?

6 Wall Street analysts have issued 1 year target prices for Amyris' stock. Their forecasts range from $3.35 to $35.00. On average, they expect Amyris' share price to reach $18.23 in the next year. This suggests a possible upside of 19.6% from the stock's current price.
View analysts' price targets for Amyris
or view top-rated stocks among Wall Street analysts.

Who are Amyris' key executives?

Amyris' management team includes the following people:
  • Mr. John G. Melo, Pres, CEO & Director (Age 55, Pay $1.34M)
  • Mr. Hermanus Kieftenbeld, CFO & Chief Admin. Officer (Age 55, Pay $817.84k)
  • Mr. Eduardo Alvarez, Chief Operating Officer (Age 57, Pay $959.76k)
  • Mr. Anthony Hughes, Chief Accounting Officer (Age 56)
  • Mr. Peter DeNardo, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 54)
  • Ms. Christine Ofori, Chief People Officer
  • Mr. Charles Kraft, Sr. VP of Global Manufacturing & Process Devel.
  • Ms. Caroline Hadfield, Pres of Aprinnova
  • Mr. Jim Iacoponi, Sr. VP of Nutrition Ingredients

What is John Melo's approval rating as Amyris' CEO?

53 employees have rated Amyris CEO John Melo on Glassdoor.com. John Melo has an approval rating of 54% among Amyris' employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amyris' key competitors?

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Who are Amyris' major shareholders?

Amyris' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.38%), Pinnacle Associates Ltd. (1.38%), Lord Abbett & CO. LLC (0.97%), Geode Capital Management LLC (0.82%), Price T Rowe Associates Inc. MD (0.37%) and Millennium Management LLC (0.35%). Company insiders that own Amyris stock include Frank Kung, John Melo, L John Doerr and Patrick Y Yang.
View institutional ownership trends for Amyris
.

Which major investors are selling Amyris stock?

AMRS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Millennium Management LLC, Victory Capital Management Inc., Morgan Stanley, MYDA Advisors LLC, Edmond DE Rothschild Holding S.A., Squarepoint Ops LLC, and Essex Investment Management Co. LLC.
View insider buying and selling activity for Amyris
or view top insider-selling stocks.

Which major investors are buying Amyris stock?

AMRS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Lord Abbett & CO. LLC, Price T Rowe Associates Inc. MD, Baird Financial Group Inc., Renaissance Technologies LLC, Geode Capital Management LLC, Pinnacle Associates Ltd., and Voloridge Investment Management LLC. Company insiders that have bought Amyris stock in the last two years include Frank Kung, and L John Doerr.
View insider buying and selling activity for Amyris
or or view top insider-buying stocks.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $15.24.

How much money does Amyris make?

Amyris has a market capitalization of $4.50 billion and generates $173.14 million in revenue each year. The biotechnology company earns $-331,040,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does Amyris have?

Amyris employs 595 workers across the globe.

What is Amyris' official website?

The official website for Amyris is amyris.com.

Where are Amyris' headquarters?

Amyris is headquartered at 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]


This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.